Ripretinib resistance management

Ripretinib is a targeted drug used to treat advanced gastrointestinal stromal tumors (GIST) with KIT or PDGFRA mutations. The phenomenon of effectively inhibiting the growth of tumor cells, that is, drug resistance, requires timely communication with the doctor. The doctor may ensure whether the patient's tumor still expresses KIT or PDGFRA mutations, and eliminate other factors that may lead to treatment failure.

Research on the use of rapatinib shows that the most reported grade 3/4 events are anemia, hypertension, abdominal pain, elevated lipase, elevated blood alkaline phosphatase and hypophosphatemia. The prescribed dose is 150mg orally administered once daily. Doctors will try to increase the dose of rapatinib to improve the inhibitory effect on tumor cells, but it needs to be judged based on the patient's overall health status and tolerance to avoid excessive toxicity. Combination therapy with other drugs may also be used to overcome drug resistance. For example, combined with other targeted drugs, chemotherapy drugs or immunotherapy.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.